{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T02:43:26Z","timestamp":1792118606264,"version":"4.4.0"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2021,8,11]],"date-time":"2021-08-11T00:00:00Z","timestamp":1628640000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,8,11]],"date-time":"2021-08-11T00:00:00Z","timestamp":1628640000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1038\/s41409-021-01427-2","type":"journal-article","created":{"date-parts":[[2021,8,11]],"date-time":"2021-08-11T12:02:59Z","timestamp":1628683379000},"page":"2637-2643","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Cardiac complications associated with hematopoietic stem-cell transplantation"],"prefix":"10.1038","volume":"56","author":[{"given":"Akihiro","family":"Ohmoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5118-7950","authenticated-orcid":false,"given":"Shigeo","family":"Fuji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,11]]},"reference":[{"key":"1427_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.7326\/M19-2936","volume":"172","author":"GB McDonald","year":"2020","unstructured":"McDonald GB, Sandmaier BM, Mielcarek M, Sorror M, Pergam SA, Cheng GS, et al. Survival, nonrelapse mortality, and relapse-related mortality after allogeneic hematopoietic cell transplantation: comparing 2003-2007 versus 2013-2017 cohorts. Ann Intern Med. 2020;172:229\u201339.","journal-title":"Ann Intern Med"},{"key":"1427_CR2","doi-asserted-by":"publisher","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","volume":"106","author":"ML Sorror","year":"2005","unstructured":"Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106:2912\u20139.","journal-title":"Blood."},{"key":"1427_CR3","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s11936-016-0447-9","volume":"18","author":"A Blaes","year":"2016","unstructured":"Blaes A, Konety S, Hurley P. Cardiovascular complications of hematopoietic stem cell transplantation. Curr Treat Options Cardiovasc Med. 2016;18:25.","journal-title":"Curr Treat Options Cardiovasc Med"},{"key":"1427_CR4","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/sj.bmt.1703133","volume":"28","author":"T Murdych","year":"2001","unstructured":"Murdych T, Weisdorf DJ. Serious cardiac complications during bone marrow transplantation at the University of Minnesota, 1977-1997. Bone Marrow Transpl. 2001;28:283\u20137.","journal-title":"Bone Marrow Transpl"},{"key":"1427_CR5","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-019-0774-6","volume":"21","author":"M Tuzovic","year":"2019","unstructured":"Tuzovic M, Mead M, Young PA, Schiller G, Yang EH. Cardiac complications in the adult bone marrow transplant patient. Curr Oncol Rep. 2019;21:28.","journal-title":"Curr Oncol Rep"},{"key":"1427_CR6","doi-asserted-by":"publisher","first-page":"2869","DOI":"10.1002\/cncr.11407","volume":"97","author":"SM Swain","year":"2003","unstructured":"Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer. 2003;97:2869\u201379.","journal-title":"Cancer."},{"key":"1427_CR7","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1200\/JCO.2016.70.5400","volume":"35","author":"SH Armenian","year":"2017","unstructured":"Armenian SH, Lacchetti C, Barac A, Carver J, Constine LS, Denduluri N, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2017;35:893\u2013911.","journal-title":"J Clin Oncol"},{"key":"1427_CR8","doi-asserted-by":"publisher","first-page":"309","DOI":"10.3322\/caac.21341","volume":"66","author":"G Curigliano","year":"2016","unstructured":"Curigliano G, Cardinale D, Dent S, Criscitiello C, Aseyev O, Lenihan D, et al. Cardiotoxicity of anticancer treatments: epidemiology, detection, and management. CA Cancer J Clin. 2016;66:309\u201325.","journal-title":"CA Cancer J Clin"},{"key":"1427_CR9","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1001\/jamaoncol.2020.5742","volume":"7","author":"MJ Ratain","year":"2021","unstructured":"Ratain MJ, Moslehi JJ, Lichter AS. Ibrutinib\u2019s cardiotoxicity\u2014an opportunity for postmarketing regulation. JAMA Oncol. 2021;7:177\u20138.","journal-title":"JAMA Oncol"},{"key":"1427_CR10","doi-asserted-by":"publisher","first-page":"e0211228","DOI":"10.1371\/journal.pone.0211228","volume":"14","author":"D Caldeira","year":"2019","unstructured":"Caldeira D, Alves D, Costa J, Ferreira JJ, Pinto FJ. Ibrutinib increases the risk of hypertension and atrial fibrillation: systematic review and meta-analysis. PLoS One. 2019;14:e0211228.","journal-title":"PLoS One"},{"key":"1427_CR11","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1016\/j.jacep.2018.06.004","volume":"4","author":"S Ganatra","year":"2018","unstructured":"Ganatra S, Sharma A, Shah S, Chaudhry GM, Martin DT, Neilan TG, et al. Ibrutinib-associated atrial fibrillation. JACC Clin Electrophysiol. 2018;4:1491\u2013500.","journal-title":"JACC Clin Electrophysiol"},{"key":"1427_CR12","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1093\/eurheartj\/ehi825","volume":"27","author":"J Heeringa","year":"2006","unstructured":"Heeringa J, van der Kuip DA, Hofman A, Kors JA, van Herpen G, Stricker BH, et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J. 2006;27:949\u201353.","journal-title":"Eur Heart J"},{"key":"1427_CR13","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1182\/hematology.2020000118","volume":"2020","author":"A Lipsky","year":"2020","unstructured":"Lipsky A, Lamanna N. Managing toxicities of Bruton tyrosine kinase inhibitors. Hematol Am Soc Hematol Educ Program. 2020;2020:336\u201345.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"1427_CR14","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1200\/JCO.19.00231","volume":"37","author":"RF Cornell","year":"2019","unstructured":"Cornell RF, Ky B, Weiss BM, Dahm CN, Gupta DK, Du L, et al. Prospective study of cardiac events during proteasome inhibitor therapy for relapsed multiple myeloma. J Clin Oncol. 2019;37:1946\u201355.","journal-title":"J Clin Oncol"},{"key":"1427_CR15","doi-asserted-by":"publisher","first-page":"2557","DOI":"10.1080\/10428194.2018.1437269","volume":"59","author":"C Shah","year":"2018","unstructured":"Shah C, Bishnoi R, Jain A, Bejjanki H, Xiong S, Wang Y, et al. Cardiotoxicity associated with carfilzomib: systematic review and meta-analysis. Leuk Lymphoma. 2018;59:2557\u201369.","journal-title":"Leuk Lymphoma"},{"key":"1427_CR16","doi-asserted-by":"publisher","first-page":"2993","DOI":"10.1200\/JCO.19.03345","volume":"38","author":"A Burchert","year":"2020","unstructured":"Burchert A, Bug G, Fritz LV, Finke J, Stelljes M, R\u00f6llig C, et al. Sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with FLT3-internal tandem duplication mutation (SORMAIN). J Clin Oncol. 2020;38:2993\u20133002.","journal-title":"J Clin Oncol"},{"key":"1427_CR17","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1111\/bcp.12387","volume":"78","author":"WX Qi","year":"2014","unstructured":"Qi WX, Shen Z, Tang LN, Yao Y. Congestive heart failure risk in cancer patients treated with vascular endothelial growth factor tyrosine kinase inhibitors: a systematic review and meta-analysis of 36 clinical trials. Br J Clin Pharm. 2014;78:748\u201362.","journal-title":"Br J Clin Pharm"},{"key":"1427_CR18","doi-asserted-by":"publisher","first-page":"I290","DOI":"10.1161\/CIRCULATIONAHA.105.001289","volume":"114","author":"I Friehs","year":"2006","unstructured":"Friehs I, Barillas R, Vasilyev NV, Roy N, McGowan FX, del Nido PJ. Vascular endothelial growth factor prevents apoptosis and preserves contractile function in hypertrophied infant heart. Circulation. 2006;114:I290\u20135.","journal-title":"Circulation."},{"key":"1427_CR19","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/S1470-2045(21)00005-X","volume":"22","author":"J Kuruvilla","year":"2021","unstructured":"Kuruvilla J, Ramchandren R, Santoro A, Paszkiewicz-Kozik E, Gasiorowski R, Johnson NA, et al. Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study. Lancet Oncol. 2021;22:512\u201324.","journal-title":"Lancet Oncol"},{"key":"1427_CR20","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1093\/cvr\/cvz026","volume":"115","author":"JR Hu","year":"2019","unstructured":"Hu JR, Florido R, Lipson EJ, Naidoo J, Ardehali R, Tocchetti CG, et al. Cardiovascular toxicities associated with immune checkpoint inhibitors. Cardiovasc Res. 2019;115:854\u201368.","journal-title":"Cardiovasc Res"},{"key":"1427_CR21","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-020-00925-8","volume":"22","author":"A Khunger","year":"2020","unstructured":"Khunger A, Battel L, Wadhawan A, More A, Kapoor A, Agrawal N. New insights into mechanisms of immune checkpoint inhibitor-induced cardiovascular toxicity. Curr Oncol Rep. 2020;22:65.","journal-title":"Curr Oncol Rep"},{"key":"1427_CR22","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","volume":"19","author":"JE Salem","year":"2018","unstructured":"Salem JE, Manouchehri A, Moey M, Lebrun-Vignes B, Bastarache L, Pariente A, et al. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncol. 2018;19:1579\u201389.","journal-title":"Lancet Oncol"},{"key":"1427_CR23","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1182\/blood.V68.5.1114.1114","volume":"68","author":"MA Goldberg","year":"1986","unstructured":"Goldberg MA, Antin JH, Guinan EC, Rappeport JM. Cyclophosphamide cardiotoxicity: an analysis of dosing as a risk factor. Blood. 1986;68:1114\u20138.","journal-title":"Blood."},{"key":"1427_CR24","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1200\/JCO.1991.9.7.1215","volume":"9","author":"AC Braverman","year":"1991","unstructured":"Braverman AC, Antin JH, Plappert MT, Cook EF, Lee RT. Cyclophosphamide cardiotoxicity in bone marrow transplantation: a prospective evaluation of new dosing regimens. J Clin Oncol. 1991;9:1215\u201323.","journal-title":"J Clin Oncol"},{"key":"1427_CR25","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1007\/s00277-016-2654-6","volume":"95","author":"S Ishida","year":"2016","unstructured":"Ishida S, Doki N, Shingai N, Yoshioka K, Kakihana K, Sakamaki H, et al. The clinical features of fatal cyclophosphamide-induced cardiotoxicity in a conditioning regimen for allogeneic hematopoietic stem cell transplantation (allo-HSCT). Ann Hematol. 2016;95:1145\u201350.","journal-title":"Ann Hematol"},{"key":"1427_CR26","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.jaccao.2021.02.011","volume":"3","author":"R Dul\u00e9ry","year":"2021","unstructured":"Dul\u00e9ry R, Mohty R, Labopin M, Sestili S, Malard F, Brissot E, et al. Early cardiac toxicity associated with post-transplant cyclophosphamide in allogeneic stem cell transplantation. JACC CardioOncol. 2021;3:250\u20139.","journal-title":"JACC CardioOncol"},{"key":"1427_CR27","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1016\/j.bbmt.2010.02.021","volume":"16","author":"SH Armenian","year":"2010","unstructured":"Armenian SH, Sun CL, Mills G, Teh JB, Francisco L, Durand JB, et al. Predictors of late cardiovascular complications in survivors of hematopoietic cell transplantation. Biol Blood Marrow Transpl. 2010;16:1138\u201344.","journal-title":"Biol Blood Marrow Transpl"},{"key":"1427_CR28","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1007\/s00277-013-1682-8","volume":"92","author":"S Sivgin","year":"2013","unstructured":"Sivgin S, Eser B. The management of iron overload in allogeneic hematopoietic stem cell transplant (alloHSCT) recipients: where do we stand? Ann Hematol. 2013;92:577\u201386.","journal-title":"Ann Hematol"},{"key":"1427_CR29","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.jtct.2020.11.007","volume":"27","author":"A Isidori","year":"2021","unstructured":"Isidori A, Loscocco F, Visani G, Chiarucci M, Musto P, Kubasch AS, et al. Iron toxicity and chelation therapy in hematopoietic stem cell transplant. Transpl Cell Ther. 2021;27:371\u20139.","journal-title":"Transpl Cell Ther"},{"key":"1427_CR30","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1038\/bmt.2015.127","volume":"50","author":"ES Tonorezos","year":"2015","unstructured":"Tonorezos ES, Stillwell EE, Calloway JJ, Glew T, Wessler JD, Rebolledo BJ, et al. Arrhythmias in the setting of hematopoietic cell transplants. Bone Marrow Transpl. 2015;50:1212\u20136.","journal-title":"Bone Marrow Transpl"},{"key":"1427_CR31","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1016\/j.bbmt.2013.05.019","volume":"19","author":"A Singla","year":"2013","unstructured":"Singla A, Hogan WJ, Ansell SM, Buadi FK, Dingli D, Dispenzieri A, et al. Incidence of supraventricular arrhythmias during autologous peripheral blood stem cell transplantation. Biol Blood Marrow Transpl. 2013;19:1233\u20137.","journal-title":"Biol Blood Marrow Transpl"},{"key":"1427_CR32","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1038\/sj.bmt.1704623","volume":"34","author":"JD Hidalgo","year":"2004","unstructured":"Hidalgo JD, Krone R, Rich MW, Blum K, Adkins D, Fan MY, et al. Supraventricular tachyarrhythmias after hematopoietic stem cell transplantation: incidence, risk factors and outcomes. Bone Marrow Transpl. 2004;34:615\u20139.","journal-title":"Bone Marrow Transpl"},{"key":"1427_CR33","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/bmt.2009.97","volume":"45","author":"E Peres","year":"2010","unstructured":"Peres E, Levine JE, Khaled YA, Ibrahim RB, Braun TM, Krijanovski OI, et al. Cardiac complications in patients undergoing a reduced-intensity conditioning hematopoietic stem cell transplantation. Bone Marrow Transpl. 2010;45:149\u201352.","journal-title":"Bone Marrow Transpl"},{"key":"1427_CR34","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1111\/ejh.13322","volume":"103","author":"K Chiengthong","year":"2019","unstructured":"Chiengthong K, Lertjitbanjong P, Thongprayoon C, Bathini T, Sharma K, Prasitlumkum N, et al. Arrhythmias in hematopoietic stem cell transplantation: a systematic review and meta-analysis. Eur J Haematol. 2019;103:564\u201372.","journal-title":"Eur J Haematol"},{"key":"1427_CR35","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.bbmt.2016.08.019","volume":"23","author":"SH Armenian","year":"2017","unstructured":"Armenian SH, Chemaitilly W, Chen M, Chow EJ, Duncan CN, Jones LW, et al. The cardiovascular disease and associated risk factors working group report. Biol Blood Marrow Transpl. 2017;23:201\u201310.","journal-title":"Biol Blood Marrow Transpl"},{"key":"1427_CR36","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1038\/bmt.2014.40","volume":"49","author":"D Lerner","year":"2014","unstructured":"Lerner D, Dandoy C, Hirsch R, Laskin B, Davies SM, Jodele S. Pericardial effusion in pediatric SCT recipients with thrombotic microangiopathy. Bone Marrow Transpl. 2014;49:862\u20133.","journal-title":"Bone Marrow Transpl"},{"key":"1427_CR37","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1111\/bjh.13357","volume":"169","author":"YC Liu","year":"2015","unstructured":"Liu YC, Chien SH, Fan NW, Hu MH, Gau JP, Liu CJ, et al. Risk factors for pericardial effusion in adult patients receiving allogeneic haematopoietic stem cell transplantation. Br J Haematol. 2015;169:737\u201345.","journal-title":"Br J Haematol"},{"key":"1427_CR38","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1038\/bmt.2010.297","volume":"46","author":"M Norkin","year":"2011","unstructured":"Norkin M, Ratanatharathorn V, Ayash L, Abidi MH, Al-Kadhimi Z, Lum LG, et al. Large pericardial effusion as a complication in adults undergoing SCT. Bone Marrow Transpl. 2011;46:1353\u20136.","journal-title":"Bone Marrow Transpl"},{"key":"1427_CR39","doi-asserted-by":"publisher","first-page":"6023","DOI":"10.1182\/blood-2011-06-358226","volume":"118","author":"SH Armenian","year":"2011","unstructured":"Armenian SH, Sun CL, Shannon T, Mills G, Francisco L, Venkataraman K, et al. Incidence and predictors of congestive heart failure after autologous hematopoietic cell transplantation. Blood. 2011;118:6023\u20139.","journal-title":"Blood."},{"key":"1427_CR40","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1182\/bloodadvances.2018019117","volume":"2","author":"SH Armenian","year":"2018","unstructured":"Armenian SH, Yang D, Teh JB, Atencio LC, Gonzales A, Wong FL, et al. Prediction of cardiovascular disease among hematopoietic cell transplantation survivors. Blood Adv. 2018;2:1756\u201364.","journal-title":"Blood Adv"},{"key":"1427_CR41","doi-asserted-by":"publisher","first-page":"5537","DOI":"10.1200\/JCO.2008.17.7428","volume":"26","author":"SH Armenian","year":"2008","unstructured":"Armenian SH, Sun CL, Francisco L, Steinberger J, Kurian S, Wong FL, et al. Late congestive heart failure after hematopoietic cell transplantation. J Clin Oncol. 2008;26:5537\u201343.","journal-title":"J Clin Oncol"},{"key":"1427_CR42","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1016\/j.bbmt.2009.06.001","volume":"15","author":"MH Qazilbash","year":"2009","unstructured":"Qazilbash MH, Amjad AI, Qureshi S, Qureshi SR, Saliba RM, Khan ZU, et al. Outcome of allogeneic hematopoietic stem cell transplantation in patients with low left ventricular ejection fraction. Biol Blood Marrow Transpl. 2009;15:1265\u201370.","journal-title":"Biol Blood Marrow Transpl"},{"key":"1427_CR43","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.bbmt.2014.10.011","volume":"21","author":"P Hurley","year":"2015","unstructured":"Hurley P, Konety S, Cao Q, Weisdorf D, Blaes A. Hematopoietic stem cell transplantation in patients with systolic dysfunction: can it be done? Biol Blood Marrow Transpl. 2015;21:300\u20134.","journal-title":"Biol Blood Marrow Transpl"},{"key":"1427_CR44","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1200\/JCO.2013.52.6582","volume":"32","author":"EJ Chow","year":"2014","unstructured":"Chow EJ, Baker KS, Lee SJ, Flowers ME, Cushing-Haugen KL, Inamoto Y, et al. Influence of conventional cardiovascular risk factors and lifestyle characteristics on cardiovascular disease after hematopoietic cell transplantation. J Clin Oncol. 2014;32:191\u20138.","journal-title":"J Clin Oncol"},{"key":"1427_CR45","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1016\/j.bbmt.2014.02.012","volume":"20","author":"EJ Chow","year":"2014","unstructured":"Chow EJ, Wong K, Lee SJ, Cushing-Haugen KL, Flowers ME, Friedman DL, et al. Late cardiovascular complications after hematopoietic cell transplantation. Biol Blood Marrow Transpl. 2014;20:794\u2013800.","journal-title":"Biol Blood Marrow Transpl"},{"key":"1427_CR46","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.annonc.2019.10.023","volume":"31","author":"G Curigliano","year":"2020","unstructured":"Curigliano G, Lenihan D, Fradley M, Ganatra S, Barac A, Blaes A, et al. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. Ann Oncol. 2020;31:171\u201390.","journal-title":"Ann Oncol"},{"key":"1427_CR47","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1756-9966-31-13","volume":"31","author":"L Roziakova","year":"2012","unstructured":"Roziakova L, Bojtarova E, Mistrik M, Dubrava J, Gergel J, Lenkova N, et al. Serial measurements of cardiac biomarkers in patients after allogeneic hematopoietic stem cell transplantation. J Exp Clin Cancer Res. 2012;31:13.","journal-title":"J Exp Clin Cancer Res"},{"key":"1427_CR48","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1016\/j.jcmg.2018.03.025","volume":"11","author":"J Liu","year":"2018","unstructured":"Liu J, Banchs J, Mousavi N, Plana JC, Scherrer-Crosbie M, Thavendiranathan P, et al. Contemporary role of echocardiography for clinical decision making in patients during and after cancer therapy. JACC Cardiovasc Imaging. 2018;11:1122\u201331.","journal-title":"JACC Cardiovasc Imaging"},{"key":"1427_CR49","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1016\/j.jcmg.2018.07.005","volume":"11","author":"H Yang","year":"2018","unstructured":"Yang H, Wright L, Negishi T, Negishi K, Liu J, Marwick TH. Research to practice: assessment of left ventricular global longitudinal strain for surveillance of cancer chemotherapeutic-related cardiac dysfunction. JACC Cardiovasc Imaging. 2018;11:1196\u2013201.","journal-title":"JACC Cardiovasc Imaging"},{"key":"1427_CR50","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.jcmg.2017.11.017","volume":"11 Pt 1","author":"E Potter","year":"2018","unstructured":"Potter E, Marwick TH. Assessment of left ventricular function by echocardiography: the case for routinely adding global longitudinal strain to ejection fraction. JACC Cardiovasc Imaging. 2018;11 Pt 1:260\u201374.","journal-title":"JACC Cardiovasc Imaging"},{"key":"1427_CR51","doi-asserted-by":"publisher","first-page":"71","DOI":"10.7863\/jum.2011.30.1.71","volume":"30","author":"S Mondillo","year":"2011","unstructured":"Mondillo S, Galderisi M, Mele D, Cameli M, Lomoriello VS, Zac\u00e0 V, et al. Speckle-tracking echocardiography: a new technique for assessing myocardial function. J Ultrasound Med. 2011;30:71\u201383.","journal-title":"J Ultrasound Med"},{"key":"1427_CR52","doi-asserted-by":"publisher","first-page":"2751","DOI":"10.1016\/j.jacc.2014.01.073","volume":"63 Pt A","author":"P Thavendiranathan","year":"2014","unstructured":"Thavendiranathan P, Poulin F, Lim KD, Plana JC, Woo A, Marwick TH. Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic review. J Am Coll Cardiol. 2014;63 Pt A:2751\u201368.","journal-title":"J Am Coll Cardiol"},{"key":"1427_CR53","doi-asserted-by":"crossref","unstructured":"Ryan TD, Moore RA, Lang SM, Khoury P, Dandoy CE, Davies SM, et al. Rapid cardiac MRI protocol for cardiac assessment in paediatric and young adult patients undergoing haematopoietic stem cell transplant: a feasibility study. Cardiol Young. 2021;31:973\u20138.","DOI":"10.1017\/S1047951120004990"},{"key":"1427_CR54","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/sj.bmt.1702507","volume":"26","author":"JA Snowden","year":"2000","unstructured":"Snowden JA, Hill GR, Hunt P, Carnoutsos S, Spearing RL, Espiner E, et al. Assessment of cardiotoxicity during haemopoietic stem cell transplantation with plasma brain natriuretic peptide. Bone Marrow Transpl. 2000;26:309\u201313.","journal-title":"Bone Marrow Transpl"},{"key":"1427_CR55","first-page":"15","volume":"11","author":"F Cai","year":"2019","unstructured":"Cai F, Luis MAF, Lin X, Wang M, Cai L, Cen C, et al. Anthracycline-induced cardiotoxicity in the chemotherapy treatment of breast cancer: preventive strategies and treatment. Mol Clin Oncol. 2019;11:15\u201323.","journal-title":"Mol Clin Oncol"},{"key":"1427_CR56","doi-asserted-by":"publisher","first-page":"e27308","DOI":"10.1002\/pbc.27308","volume":"65","author":"V Gupta","year":"2018","unstructured":"Gupta V, Kumar Singh S, Agrawal V, Bali Singh T. Role of ACE inhibitors in anthracycline-induced cardiotoxicity: a randomized, double-blind, placebo-controlled trial. Pediatr Blood Cancer. 2018;65:e27308.","journal-title":"Pediatr Blood Cancer"},{"key":"1427_CR57","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1161\/CIRCULATIONAHA.106.635144","volume":"114","author":"D Cardinale","year":"2006","unstructured":"Cardinale D, Colombo A, Sandri MT, Lamantia G, Colombo N, Civelli M, et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation. 2006;114:2474\u201381.","journal-title":"Circulation."},{"key":"1427_CR58","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.1016\/j.jacc.2013.02.072","volume":"61","author":"X Bosch","year":"2013","unstructured":"Bosch X, Rovira M, Sitges M, Dom\u00e8nech A, Ortiz-P\u00e9rez JT, de Caralt TM, et al. Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (prevention of left ventricular dysfunction with enalapril and carvedilol in patients submitted to intensive chemotherapy for the treatment of Malignant hemopathies). J Am Coll Cardiol. 2013;61:2355\u201362.","journal-title":"J Am Coll Cardiol"},{"key":"1427_CR59","doi-asserted-by":"publisher","first-page":"e131","DOI":"10.1016\/j.ddtec.2012.05.001","volume":"9","author":"TH Langenickel","year":"2012","unstructured":"Langenickel TH, Dole WP. Angiotensin receptor-neprilysin inhibition with LCZ696: a novel approach for the treatment of heart failure. Drug Discov Today: Therapeutic Strateg. 2012;9:e131\u20139.","journal-title":"Drug Discov Today: Therapeutic Strateg"},{"key":"1427_CR60","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1111\/j.1742-1241.2006.00817.x","volume":"60","author":"S Sulfi","year":"2006","unstructured":"Sulfi S, Timmis AD. Ivabradine \u2013 the first selective sinus node I(f) channel inhibitor in the treatment of stable angina. Int J Clin Pr. 2006;60:222\u20138.","journal-title":"Int J Clin Pr"},{"key":"1427_CR61","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","volume":"371","author":"JJ McMurray","year":"2014","unstructured":"McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993\u20131004.","journal-title":"N Engl J Med"},{"key":"1427_CR62","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1016\/S0140-6736(12)61227-6","volume":"380","author":"SD Solomon","year":"2012","unstructured":"Solomon SD, Zile M, Pieske B, Voors A, Shah A, Kraigher-Krainer E, et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet. 2012;380:1387\u201395.","journal-title":"Lancet."},{"key":"1427_CR63","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/S0140-6736(10)61198-1","volume":"376","author":"K Swedberg","year":"2010","unstructured":"Swedberg K, Komajda M, B\u00f6hm M, Borer JS, Ford I, Dubost-Brama A, et al. Ivabradine and outcomes in chroni c heart failure (SHIFT): a randomised placebo-controlled study. Lancet. 2010;376:875\u201385.","journal-title":"Lancet."},{"key":"1427_CR64","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","volume":"37","author":"P Ponikowski","year":"2016","unstructured":"Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37:2129\u2013200.","journal-title":"Eur Heart J"},{"key":"1427_CR65","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1200\/JCO.2015.60.8851","volume":"34","author":"BL Asselin","year":"2016","unstructured":"Asselin BL, Devidas M, Chen L, Franco VI, Pullen J, Borowitz MJ, et al. Cardioprotection and safety of dexrazoxane in patients treated for newly diagnosed T-cell acute lymphoblastic Leukemia or advanced-stage lymphoblastic non-Hodgkin lymphoma: a report of the Children\u2019s Oncology Group Randomized Trial Pediatric Oncology Group 9404. J Clin Oncol. 2016;34:854\u201362.","journal-title":"J Clin Oncol"},{"key":"1427_CR66","first-page":"CD003917","volume":"2011","author":"EC van Dalen","year":"2011","unstructured":"van Dalen EC, Caron HN, Dickinson HO, Kremer LC. Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev. 2011;2011:CD003917.","journal-title":"Cochrane Database Syst Rev"},{"key":"1427_CR67","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1200\/JCO.2011.34.8987","volume":"30","author":"JG Blanco","year":"2012","unstructured":"Blanco JG, Sun CL, Landier W, Chen L, Esparza-Duran D, Leisenring W, et al. Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes-a report from the Children\u2019s Oncology Group. J Clin Oncol. 2012;30:1415\u201321.","journal-title":"J Clin Oncol"},{"key":"1427_CR68","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1200\/JCO.2010.34.3467","volume":"30","author":"H Visscher","year":"2012","unstructured":"Visscher H, Ross CJ, Rassekh SR, Barhdadi A, Dub\u00e9 MP, Al-Saloos H, et al. Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children. J Clin Oncol. 2012;30:1422\u20138.","journal-title":"J Clin Oncol"},{"key":"1427_CR69","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1200\/JCO.2015.63.4550","volume":"34","author":"X Wang","year":"2016","unstructured":"Wang X, Sun CL, Qui\u00f1ones-Lombra\u00f1a A, Singh P, Landier W, Hageman L, et al. CELF4 variant and anthracycline-related cardiomyopathy: a Children\u2019s Oncology Group genome-wide association Study. J Clin Oncol. 2016;34:863\u201370.","journal-title":"J Clin Oncol"},{"key":"1427_CR70","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.jaccao.2020.09.006","volume":"2","author":"S Bhatia","year":"2020","unstructured":"Bhatia S. Genetics of anthracycline cardiomyopathy in cancer survivors: JACC: CardioOncology state-of-the-art review. JACC CardioOncol. 2020;2:539\u201352.","journal-title":"JACC CardioOncol"},{"key":"1427_CR71","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1093\/cvr\/cvz031","volume":"115","author":"EJ Chow","year":"2019","unstructured":"Chow EJ, Leger KJ, Bhatt NS, Mulrooney DA, Ross CJ, Aggarwal S, et al. Paediatric cardio-oncology: epidemiology, screening, prevention, and treatment. Cardiovasc Res. 2019;115:922\u201334.","journal-title":"Cardiovasc Res"},{"key":"1427_CR72","doi-asserted-by":"publisher","first-page":"S263","DOI":"10.1016\/j.cjca.2018.07.001","volume":"34 Suppl 2","author":"D Rothe","year":"2018","unstructured":"Rothe D, Cox-Kennett N, Buijs DM, Venner CP, Paterson DI, Gyenes GT, et al. Cardiac rehabilitation in patients with lymphoma undergoing autologous hematopoietic stem cell transplantation: a cardio-oncology pilot project. Can J Cardiol. 2018;34 Suppl 2:S263\u20139.","journal-title":"Can J Cardiol"},{"key":"1427_CR73","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s00520-020-05485-y","volume":"29","author":"M Limbach","year":"2021","unstructured":"Limbach M, Kuehl R, Dreger P, Luft T, Rosenberger F, Kleindienst N, et al. Influencing factors of cardiorespiratory fitness in allogeneic stem cell transplant candidates prior to transplantation. Support Care Cancer. 2021;29:359\u201367.","journal-title":"Support Care Cancer"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-021-01427-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-021-01427-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-021-01427-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,2]],"date-time":"2021-11-02T10:21:01Z","timestamp":1635848461000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-021-01427-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,11]]},"references-count":73,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["1427"],"URL":"https:\/\/doi.org\/10.1038\/s41409-021-01427-2","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,11]]},"assertion":[{"value":"23 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}